Gilead Sciences (NASDAQ:GILD) Issues Earnings Results

Gilead Sciences (NASDAQ:GILD) issued its earnings results on Tuesday. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.23, Zacks reports. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Gilead Sciences updated its FY 2025 guidance to 7.700-8.100 EPS.

Gilead Sciences Stock Up 0.7 %

Gilead Sciences stock opened at $96.14 on Wednesday. The company has a fifty day simple moving average of $93.07 and a 200 day simple moving average of $86.99. Gilead Sciences has a 1-year low of $62.07 and a 1-year high of $100.51. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The company has a market cap of $119.82 billion, a P/E ratio of 1,068.22, a price-to-earnings-growth ratio of 1.25 and a beta of 0.18.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on GILD. Leerink Partners raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $74.00 to $96.00 in a research note on Monday, October 21st. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday. Morgan Stanley upped their price objective on Gilead Sciences from $113.00 to $123.00 and gave the company an “overweight” rating in a report on Wednesday. Truist Financial raised their target price on Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a report on Friday, November 8th. Finally, Maxim Group cut Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Eleven analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and an average target price of $98.83.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 248,645 shares of the firm’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the transaction, the chief financial officer now directly owns 138,919 shares of the company’s stock, valued at approximately $12,886,126.44. This trade represents a 64.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey Bluestone sold 6,788 shares of the company’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the sale, the director now directly owns 8,920 shares in the company, valued at $815,198.80. This trade represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 572,824 shares of company stock worth $53,611,715 in the last quarter. Corporate insiders own 0.16% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.